GSK 6-K
GSK plc (GSK)
6-K
2026-07-28
For: 2026-07-28
View Original
Added on
July 28, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 28 July 2026, London UK
GSK to establish new flagship R&D centre on Cambridge
Biomedical Campus, UK
●
Investment
further integrates company into world-class ecosystem of biomedical
research, patient care and academia
●
Catalyst
to fuel collaboration and accelerate GSK R&D and medicine
development
●
£400
million investment in UK life sciences
GSK plc (LSE/NYSE: GSK) today announced plans to establish a major
new global R&D centre in Cambridge, UK, as part of the
company's plan to accelerate its R&D pipeline. The new 300,000
square foot site, on the Cambridge Biomedical Campus in the heart
of the UK's life sciences "Golden Triangle," will be home to GSK's
R&D operations in the UK and more than 1,000 GSK
scientists.
The Cambridge Biomedical Campus is one of the largest biomedical
campuses in Europe. The new location will provide GSK scientists
with direct access to a world-class ecosystem of biomedical
research, patient care and academia, enabling translational
research by bridging laboratory science with clinical
practice.
The GSK site will feature state-of-the-art, tech-enabled labs and
infrastructure to support research in the company's focus areas of
Oncology, Respiratory, Hepatology, Vaccines and HIV.
The Cambridge Biomedical Campus is home to more than 22,000 people
working in life sciences, with more than 37,000 people visiting
every day. More than 1 million patients are treated on the campus
every year, and over 470 biopharma/ biotech and AI companies are
located there. These include many existing GSK partners and
collaborations, such as, the Cambridge Centre for Data-Driven
Discovery; Cambridge-GSK Translational Immunology Collaboration;
Cambridge-GSK Metabolic Science Collaboration; Cambridge Immune
Ageing; GSK-Teichmann Lab; and GSK's Clinical Unit at Addenbrooke's
Hospital.
Luke Miels, Chief Executive Officer, GSK, said: "This
investment will accelerate our R&D and help us deliver new,
competitive products. It integrates GSK further into one of the
world's leading centres of knowledge and demonstrates the
attractiveness of the UK's life sciences
ecosystem."
Tony Wood, Chief Scientific Officer, GSK, said: "Cambridge
has built one of the world's best life sciences ecosystems, with
leading universities, hospitals and biotech companies. The campus
provides exceptional opportunities for collaboration. With our
existing connections and experience, we see this move as a catalyst
for faster, bolder medicines discovery by accelerating the science
that matters most for GSK's next wave of
medicines."
The site in Cambridge, currently in development by Prologis, will
be part of GSK's wider UK network of collaboration with leading
academic institutions and pioneering scientific organisations,
including the University of Oxford, Kings College London, Imperial
College, the University of Manchester, Wellcome and the Crick
Institute.
As a result of the planned move to Cambridge, GSK will vacate its
R&D site at Stevenage, Hertfordshire, with a phased move for
employees by 2029. Alongside the move to Cambridge, GSK will also
upgrade its existing R&D laboratories at Ware in Hertfordshire
and move some employees there to create a fully integrated drug
development and commercial manufacturing scale up capability.
Overall, the company plans to invest £400 million over 3 years
in support of these changes.
GSK will retain its global headquarters in London, which is
unaffected by today's announcement.
GSK invests over £6 billion in R&D every year of which
more than £1.5 billion is in the UK.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Sarah Clements
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Sam Piper
|
+44 (0) 7824 525779
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2025, and
GSK's Q2 Results for 2026.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
28, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|